<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-MSC-2285</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2285</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МАТЕРИАЛЫ ФОРУМА "ДНИ ИММУНОЛОГИИ В СПБ" 2021</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ НА ИММУНОКОМПЕТЕНТНЫЕ КЛЕТКИ ПРИ ТЕРАПИИ МЕЗЕНХИМАЛЬНЫМИ СТВОЛОВЫМИ КЛЕТКАМИ В СРАВНЕНИИ С ТЕРАПИЕЙ НА ОСНОВЕ МИКРОВЕЗИКУЛ У МЫШЕЙ С ХРОНИЧЕСКИМ ЗАБОЛЕВАНИЕМ ПОЧЕК</article-title><trans-title-group xml:lang="en"><trans-title>MESENCHYMAL STEM CELLS COMPARED WITH MICROVESICLES-BASED THERAPY IMPACTS IMMUNOCOMPETENT CELLS IN MICE WITH CHRONIC RENAL DISEASE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4534-2402</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хабалова</surname><given-names>Т. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Khabalova</surname><given-names>T. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>младший научный сотрудник лаборатории клеточных биотехнологий,</p><p>630099, г. Новосибирск, ул. Ядринцевская, 14</p></bio><bio xml:lang="en"><p>Junior Reseach Associate, Laboratory of Cellular Biotechnology, </p><p>630099, Novosibirsk, Yadrintsevskaya str., 14</p></bio><email xlink:type="simple">khabalovat@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1674-1439</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андросова</surname><given-names>Ю. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Androsova</surname><given-names>Yu. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ординатор лаборатории клеточных биотехнологий,</p><p>630099, г. Новосибирск, ул. Ядринцевская, 14</p></bio><bio xml:lang="en"><p>Resident, Laboratory of Cellular Biotechnology, </p><p>630099, Novosibirsk, Yadrintsevskaya str., 14</p></bio><email xlink:type="simple">Androsovaaa.ja@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8088-076X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кащенко</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaschenko</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., научный сотрудник лаборатории клеточных биотехнологий,</p><p>630099, г. Новосибирск, ул. Ядринцевская, 14</p></bio><bio xml:lang="en"><p>PhD (Medicine), Reseach Associate, Laboratory of Cellular Biotechnology,</p><p>630099, Novosibirsk, Yadrintsevskaya str., 14</p></bio><email xlink:type="simple">kaschenko.erika@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1435-2616</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванова</surname><given-names>И. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanova</surname><given-names>I. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник лаборатории клеточных биотехнологий,</p><p>630099, г. Новосибирск, ул. Ядринцевская, 14</p></bio><bio xml:lang="en"><p>PhD (Medicine), Senior Reseach Associate, Laboratory of Cellular Biotechnology,</p><p>630099, Novosibirsk, Yadrintsevskaya str., 14</p></bio><email xlink:type="simple">irinaiki@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Fundamental and Clinical Immunology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>08</day><month>10</month><year>2021</year></pub-date><volume>23</volume><issue>4</issue><fpage>685</fpage><lpage>692</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хабалова Т.С., Андросова Ю.Э., Кащенко Э.А., Иванова И.П., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Хабалова Т.С., Андросова Ю.Э., Кащенко Э.А., Иванова И.П.</copyright-holder><copyright-holder xml:lang="en">Khabalova T.S., Androsova Y.E., Kaschenko E.A., Ivanova I.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2285">https://www.mimmun.ru/mimmun/article/view/2285</self-uri><abstract><p>Мезенхимальные стволовые клетки, которые обладают как плюрипотентными, так и иммунорегуляторными функциями, активно изучаются как один из способов лечения во многих областях медицины, включая реабилитацию в нефрологии. Однако в некоторых статьях, посвященных лечению различных органических патологий с помощью МСК, было доказано, что эффекты от применения МСК в регенеративной медицине заключаются в том, что после трансплантации в поврежденные органы они могут ингибировать апоптоз клеток, способствуют ангиогенезу для лучшего кровоснабжения и в некоторых случаях стимулируют местную пролиферацию клеток в поврежденных тканях. Другими словами, про-регенерационные функции были обусловлены их паракринными эффектами без влияния дифференциации.</p><p>При введении мышам МСК было показано иммуноподавляющее действие, что в конечном счете приводило к уменьшению воспаления и улучшенной регенерации почек. Одним из механизмов восстановления могут быть МВ – внеклеточные тельца, продуцируемые МСК. Как стало известно из последних сообщений, МВ сохраняют некоторые функции клеток, такие как перенос микроРНК и т.д. Считается, что терапевтический эффект МСК может быть во многом связан с их иммуносупрессорными свойствами.</p><p>Целью данного исследования было изучение иммунорегуляторных свойств микровезикул (МСКМВ, МВ) в сравнении с мезенхимальными стволовыми клетками (МСК). Эксперимент проводился на мышах линии CBA возрастом 3-4 месяца, использовалась модель глицерол-индуцированной хронической почечной недостаточности (ХПН). МСК были получены из костного мозга сингенных мышей большеберцовой и бедренной костей. Клетки культивировались в культуральном матрасе до достижения монослоя. МВ были получены из МСК путем апоптоза при помощи культивирования в бессывороточной среде в условиях депривации кислорода в течении суток. МСК и МСК-МВ вводились в хвостовую вену мышей, забор органов производился на 11-е сутки после введения МСК и МСК-МВ.</p><p>Методом проточной цитофлуориметрии оценили состояние клеточного иммунитета у мышей с хронической почечной недостаточностью (ХПН) после введения мезенхимальных стволовых клеток (МСК) и полученных из них микровезикул (МСК-МВ) на 11-е сутки эксперимента. В результате наблюдалось снижение количества Т-регуляторных клеток CD4+CD25+Foxp3+, повышение содержания CD4+CD44+CD62+ и CD8+CD44+CD62+ Т-клеток памяти.</p><p>Влияние МВ не существенно отличалось от МСК. Это может свидетельствовать о том, что терапевтические свойства МСК обусловлены в большей степени, если не полностью МСК-МВ.</p></abstract><trans-abstract xml:lang="en"><p>Mesenchymal stem cells which have both pluripotent and immunoregulatory functions are being actively studied as one of the treatment ways in many fields of medicine, including rehabilitation in nephrology. However, in some articles were dedicated to the treatment of different organic pathology with MSC’s was proved that the only reported effects from the application of MSC’s in regenerative medicine are that, after transplantation to damaged organs, in a paracrine manner they may inhibit apoptosis of cells, promote angiogenesis for a better blood supply, and in some cases stimulate cells that have survived in damaged tissues to proliferate in order to replenish dying tissue fragments. In other words, the pro-reparational functions were due to their paracrine effects without the impact of differentiation. Microvesicles are one of the components of this pro-regenerative effect. And although immunoregulatory action has been shown for MSCs, it remains poorly understood for microvesicles.</p><p>The aim of this study was to study the immunoregulatory properties of microvesicles (MSC-MB, MB) in comparison with mesenchymal stem cells (MSC). The experiment was carried out on CBA mice 3-4 months old, a model of glycerol-induced chronic renal failure (CRF) was used. MSCs were obtained from the bone marrow of syngeneic mice of the tibia and femur. MVs were obtained by apoptosis by culturing in a serum-free medium under oxygen deprivation conditions. MSC and MSC-MB were injected into the tail vein of mice; organs were harvested on the 11th day after administration of MSC and MSC-MB.</p><p>The state of cellular immunity in mice with chronic renal failure (CRF) after the introduction of mesenchymal stem cells (MSC) and microvesicles derived from them (MSC-MB) on the 11th day of the experiment was assessed by flow cytometry. As a result, there was a decrease in the number of T-regulatory cells CD4+ CD25+ Foxp3+, an increase in the content of CD4+ CD44+ CD62+ and CD8+ CD44+ CD62+ memory T-cells.</p><p>The effect of MVs was not significantly different from that of MSC. This may indicate that the therapeutic properties of MSCs are determined to a greater extent, if not completely, by MSC-MB. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>мезенхимальные стволовые клетки</kwd><kwd>внеклеточные пузырьки</kwd><kwd>микровезикулы</kwd><kwd>хроническая почечная недостаточность</kwd><kwd>почечное повреждение</kwd><kwd>бесклеточная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>mesenchymal stem cells</kwd><kwd>microvesicles</kwd><kwd>microvesicles</kwd><kwd>chronic renal failure</kwd><kwd>chronic kidney disease</kwd><kwd>acellular therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Alikhan M.A., Huynh M., Kitching A.R., Ooi J.D. Regulatory T cells in renal disease. Clin. Transl. Immunol., 2018, Vol. 7, no. 1, 1004. doi: 10.1002/cti2.1004.</mixed-citation><mixed-citation xml:lang="en">Alikhan M.A., Huynh M., Kitching A.R., Ooi J.D. Regulatory T cells in renal disease. Clin. Transl. Immunol., 2018, Vol. 7, no. 1, 1004. doi: 10.1002/cti2.1004.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bonventre J.V., Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int., 2004, Vol. 66, pp. 480-485.</mixed-citation><mixed-citation xml:lang="en">Bonventre J.V., Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int., 2004, Vol. 66, pp. 480-485.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Burne M.J., Daniels F., El Ghandour A., Mauiyyedi S., Colvin R.B., O’Donnell M.P., Rabb H. Identification of the CD4( þ) T cell as a major pathogenic factor in ischemic acute renal failure. J. Clin. Invest., 2001, Vol. 108, no. 9, pp. 1283-1290.</mixed-citation><mixed-citation xml:lang="en">Burne M.J., Daniels F., El Ghandour A., Mauiyyedi S., Colvin R.B., O’Donnell M.P., Rabb H. Identification of the CD4( þ) T cell as a major pathogenic factor in ischemic acute renal failure. J. Clin. Invest., 2001, Vol. 108, no. 9, pp. 1283-1290.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Goes N., Urmson J., Ramassar V., Halloran P.F. Ischemic acute tubular necrosis induces an extensive local cytokine response: evidence for induction of interferon-, transforming growth factor-1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation, 1995, Vol. 59, no. 4, pp. 565-572.</mixed-citation><mixed-citation xml:lang="en">Goes N., Urmson J., Ramassar V., Halloran P.F. Ischemic acute tubular necrosis induces an extensive local cytokine response: evidence for induction of interferon-, transforming growth factor-1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation, 1995, Vol. 59, no. 4, pp. 565-572.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta K.H., Goldufsky J.W., Wood S.J., Tardi N.J., Moorthy G.S., Gilbert D.Z., Zayas J.P., Hahm E., Altintas M.M., Reiser J., Shafikhani S.H. Apoptosis and compensatory proliferation signaling are coupled by CrkIcontaining microvesicles. Dev. Cell, 2017, Vol. 41, no. 6, pp. 674-684.</mixed-citation><mixed-citation xml:lang="en">Gupta K.H., Goldufsky J.W., Wood S.J., Tardi N.J., Moorthy G.S., Gilbert D.Z., Zayas J.P., Hahm E., Altintas M.M., Reiser J., Shafikhani S.H. Apoptosis and compensatory proliferation signaling are coupled by CrkIcontaining microvesicles. Dev. Cell, 2017, Vol. 41, no. 6, pp. 674-684.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kamijo-Ikemori A.K., Sugaya T., Matsui K., Yokoyama T., Kimura K. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology, 2011, Vol. 16, no. 6, pp 539-544.</mixed-citation><mixed-citation xml:lang="en">Kamijo-Ikemori A.K., Sugaya T., Matsui K., Yokoyama T., Kimura K. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology, 2011, Vol. 16, no. 6, pp 539-544.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Karpman D., Ståhl An-L., Arvidsson I. Extracellular vesicles in renal disease. Nat. Rev. Nephrol., 2017, Vol. 13, no. 9, pp. 545-562.</mixed-citation><mixed-citation xml:lang="en">Karpman D., Ståhl An-L., Arvidsson I. Extracellular vesicles in renal disease. Nat. Rev. Nephrol., 2017, Vol. 13, no. 9, pp. 545-562.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mause S.F., Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ. Res., 2010, Vol. 107, no. 9, pp. 1047-1057.</mixed-citation><mixed-citation xml:lang="en">Mause S.F., Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ. Res., 2010, Vol. 107, no. 9, pp. 1047-1057.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal sells. Blood, 2007, Vol. 110, no. 10, pp. 3499-3506.</mixed-citation><mixed-citation xml:lang="en">Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal sells. Blood, 2007, Vol. 110, no. 10, pp. 3499-3506.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rabb H. Immune modulation of acute kidney injury. J. Am. Soc. Nephrol., 2006, Vol. 17, no. 3, pp. 604-606.</mixed-citation><mixed-citation xml:lang="en">Rabb H. Immune modulation of acute kidney injury. J. Am. Soc. Nephrol., 2006, Vol. 17, no. 3, pp. 604-606.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ratajczak M.Z., Ratajczak J. Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future? Leukemia, 2020, Vol. 34, pp. 3126-3135.</mixed-citation><mixed-citation xml:lang="en">Ratajczak M.Z., Ratajczak J. Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future? Leukemia, 2020, Vol. 34, pp. 3126-3135.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ratajczak M.Z., Ratajczak D., Pedziwiatr D. Extracellular microvesicles (ExMVs) in cell-to-cell communication: a role of telocytes. Adv. Exp. Med. Biol., 2016, Vol. 913, pp. 41-49.</mixed-citation><mixed-citation xml:lang="en">Ratajczak M.Z., Ratajczak D., Pedziwiatr D. Extracellular microvesicles (ExMVs) in cell-to-cell communication: a role of telocytes. Adv. Exp. Med. Biol., 2016, Vol. 913, pp. 41-49.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ryu J.-S., Jeong E.-J., Kim J.-Y., Park S.J., W.S. Ju, Kim C.-H., Kim J.-S., Choo Y.-K. Application of mesenchymal stem cells in inflammatory and fibrotic disease. Int. J. Mol. Sci., 2020, Vol. 21., no. 21, 8366. doi: 10.3390/ijms21218366.</mixed-citation><mixed-citation xml:lang="en">Ryu J.-S., Jeong E.-J., Kim J.-Y., Park S.J., W.S. Ju, Kim C.-H., Kim J.-S., Choo Y.-K. Application of mesenchymal stem cells in inflammatory and fibrotic disease. Int. J. Mol. Sci., 2020, Vol. 21., no. 21, 8366. doi: 10.3390/ijms21218366.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ståhl A., Johanson K., Mossberg M., Kahn R., Karpman D. Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. Pediatr. Nephrol., 2019, Vol. 34, no. 1, pp. 11-30.</mixed-citation><mixed-citation xml:lang="en">Ståhl A., Johanson K., Mossberg M., Kahn R., Karpman D. Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. Pediatr. Nephrol., 2019, Vol. 34, no. 1, pp. 11-30.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zager R.A., Jonson A.C., Lund S., Hanson S. Acute renal failure: determinants and characteristics of injuryinduced hyperinflammatory response. Am. J. Physiol. Renal Physiol., 2006, Vol. 291, no. 3, pp. 546-556.</mixed-citation><mixed-citation xml:lang="en">Zager R.A., Jonson A.C., Lund S., Hanson S. Acute renal failure: determinants and characteristics of injuryinduced hyperinflammatory response. Am. J. Physiol. Renal Physiol., 2006, Vol. 291, no. 3, pp. 546-556.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
